Рак простаты

<![CDATA[ADI-212 Receives FDA IND Clearance for Castration-Resistant Prostate Cancer]]>

Use of active surveillance ‘encouraging’ in early prostate cancer

Use of active surveillance for early prostate cancer increased sharply in the VA healthcare system over the past couple decades, according to a research letter published in JAMA. Adoption of the approach tripled among men with low-risk prostate cancer and quadrupled among those with favorable intermediate-risk…

Statin use may counter CV risk linked to leuprolide

Statin therapy may attenuate much of the atherogenic effects associated with leuprolide for treatment of prostate cancer, according to a post hoc analysis of the REVELUTION trial published in JACC: CardioOncology. CVD is the leading cause of the death in men with prostate cancer, and adding statin therapy to…

Five-session prostate radiation better preserves bowel quality of life, trial finds

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk prostate cancer indicate that SBRT improved bowel health-related quality of life…

CRISPR makes prostate cancer vulnerable to immunotherapy

Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental treatment dramatically improved the effects of immunotherapy in mice and may offer hope for other hard-to-treat tumors.